{
    "nct_id": "NCT06179511",
    "official_title": "A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies",
    "inclusion_criteria": "* ≥18 years of age;\n* CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;\n\n  * R/R AML (except APL);\n  * R/R HR-MDS with ≥5% bone marrow blast at time of inclusion;\n* Had at least 1 prior line of therapy at currents histology, and have no available treatment options;\n* ECOG performance status of ≤ 2.\n\nThe above is a summary, other inclusion criteria details may apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active CNS leukemia;\n* Previous treatment with any CD123 targeting therapy;\n* Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy;\n* Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829;\n* History of other malignancy(with certain exceptions);\n* Active and uncontrolled infections;\n* Unresolved AEs ≥2 Grade, from prior therapies.\n\nThe above is a summary, other exclusion criteria details may apply.",
    "miscellaneous_criteria": ""
}